Ptc Therapeutics (PTCT) Interest Expenses (2012 - 2026)
Ptc Therapeutics (PTCT) posted quarterly Interest Expenses of $228.0 million for Q2 2026, up 190.8% year-over-year from $78.4 million in Q2 2025, and up 46.67% quarter-over-quarter from $155.4 million in Q1 2026.
Ptc Therapeutics (PTCT) Interest Expenses (2012 - 2026) Analysis & Trends
Ptc Therapeutics' Interest Expenses history runs 15 years deep, the most recent figure standing at $228.0 million for Q2 2026.
- In Q2 2026, Interest Expenses rose 190.8% year-over-year to $228.0 million; the TTM figure through Jun 2026 stood at $228.0 million (up 190.8% YoY), while the FY2025 annual figure was $816.5 million, down 4.79% from the prior year.
- Interest Expenses for Q2 2026 stood at $228.0 million, up from $155.4 million in the prior quarter.
- The five-year high for Interest Expenses was $228.0 million in Q2 2026, with the low at -$143.3 million in Q4 2024.
- The 5-year median for Interest Expenses is $52.3 million (2022), against an average of $56.7 million.
- The sharpest annual moves came in 2022 and 2024: Interest Expenses surged 493.81% in 2022, then tumbled 2051.29% in 2024.
- Ptc Therapeutics' Interest Expenses stood at $14.4 million in 2022, then slumped by 48.98% to $7.3 million in 2023, then sank by 2051.29% to -$143.3 million in 2024, then soared by 150.22% to $71.9 million in 2025, then soared by 216.91% to $228.0 million in 2026.
- Business Quant data shows PTCT's Interest Expenses at $228.0 million in Q2 2026, $155.4 million in Q1 2026, and $71.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Ptc Therapeutics | 5.97 Bn | 3.75 Bn | 340.60 Mn | 227.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 227.99 Mn |
| Jun 30, 2026 | 227.99 Mn |
| Mar 31, 2026 | 155.44 Mn |
| Mar 31, 2026 | 155.44 Mn |
| Dec 31, 2025 | -42.66 Mn |
| Dec 31, 2025 | -42.66 Mn |
| Sep 30, 2025 | 151.19 Mn |
| Sep 30, 2025 | 151.19 Mn |
| Jun 30, 2025 | 78.40 Mn |
| Jun 30, 2025 | 78.40 Mn |
| Mar 31, 2025 | 51.34 Mn |
| Mar 31, 2025 | 51.34 Mn |
| Dec 31, 2024 | 54.12 Mn |
| Dec 31, 2024 | 54.12 Mn |
| Sep 30, 2024 | 54.43 Mn |
| Sep 30, 2024 | 54.43 Mn |
| Jun 30, 2024 | 53.98 Mn |
| Jun 30, 2024 | 53.98 Mn |
| Mar 31, 2024 | 51.77 Mn |
| Mar 31, 2024 | 51.77 Mn |